Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

Dicerna Pharmaceuticals, Inc.

BASE mRNA facility focuses on messenger RNA design, manufacturing, and research. They provide end-to-end research services to design, manufacture, and test new mRNA medicines.

BASE mRNA facility

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc.

Novo Nordisk focuses on diabetes care and hormone replacement therapy, self-described as a leader in this sector.

Metric
Company Name	Dicerna Pharmaceuticals, Inc.	BASE mRNA facility	Alnylam Pharmaceuticals, Inc.	Corbus Pharmaceuticals Holdings, Inc.
Symbol	DRNA		ALNY	CRBP
MSH ID	COM:DICERNA	AU:ORG:BASEFACILITY	COM:ALNYLAM	COM:CORBUSPHARMA
Market	STOCKS	PRIVATE	STOCKS	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	AU	US	US
Stage	Post-IPO Equity			Post-IPO Equity
Employee Count	302		2.10K	19
Website	dicerna.com	basefacility.org.au	alnylam.com	corbuspharma.com
LinkedIn		base-facility
Founders

Metric
Market Cap		32.60B	550.26M
Enterprise Value
Monthly Web Traffic	900.07K	55.97K	4.09K
Web Traffic Growth	0.05	0.89	-0.53
Valuation
Raised Capital	22M	900M	94.50M

Metric
Revenue			1.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit			1.52B
EBITDA			-228.12M
Operating Income			-282.18M
Net Income			-440.24M
EPS			-3.52
Diluted EPS			-3.52
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.87
Operating Profit Margin			0.04
EBITDA Margin			-0.12
Net Profit Margin			-0.03
Return on Equity			1.67
Return on Assets			-0.02
Return on Capital Employed			0.03

DRNA

COM:DICERNA

Novo Nordisk

Last Close

38.22

01/01 00:00

Volume Today

5.54M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-42.10
P/B Ratio			-129.43
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			16.84
EV Multiple			326.32

Metric
Days Sales Outstanding			68.92
Days Payables Outstanding			97.72
Days Inventory Outstanding			128.53
Operating Cycle			187.09
Cash Conversion Cycle			104.98
Asset Turnover			0.58

Metric
Operating Cash Flow			104.16M
Free Cash Flow			41.95M
Cash Flow to Debt			0.15
Operating Cash Flow/Sales			0.16
Free Cash Flow Yield			-0.00

Metric
Cash & Equivalents			812.69M
Accounts Receivable			-87.94M
Inventory			89.15M
Goodwill
Debt to Capitalization			1.20
Debt to Assets			0.34
Current Ratio			3.14
Quick Ratio			3.07

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.13
R&D to Revenue			0.58
SG&A to Revenue			0.35